摘要
目的观察通心络胶囊用于冠心病患者经皮冠状动脉介入治疗(PCI)术后的临床效果。方法选取2017年5月-2019年2月辽宁省丹东市人民医院心内科诊治的冠心病患者118例,均接受急诊PCI术治疗。采用随机数字表法分为观察组和对照组各59例。对照组给予常规术后治疗,观察组在对照组治疗的基础上给予通心络胶囊治疗。比较2组患者治疗前、治疗4周后炎性因子水平,随访6个月再狭窄、心血管事件发生率及不良反应发生率。结果治疗4周后,2组超敏C反应蛋白(hs-CRP)、白介素-6(IL-6)及肿瘤坏死因子-α(TNF-α)水平均低于治疗前(P<0.05),且观察组低于对照组(P<0.01)。随访6个月,观察组支架内再狭窄发生率及狭窄程度均低于对照组(P<0.05)。观察组心血管事件发生率为6.78%,低于对照组的20.34%(χ~2=4.628,P=0.031)。2组不良反应发生率比较差异无统计学意义(χ~2=0.069,P=0.793)。2组患者均未出现严重不良反应,未停药。结论通心络胶囊用于PCI术后患者效果好,有助于缓解炎性反应,预防心血管事件、支架内再狭窄发生,且用药安全性高,值得临床推广。
Objective To observe the clinical effect of Tongxinluo capsule on patients with coronary heart disease after percutaneous coronary intervention(PCI).Methods 118 patients with coronary heart disease diagnosed and treated in Department of Cardiology in the People’s Hospital of Dandong from May 2017 to February 2019 were selected,and all of them received emergency PCI.They were randomly divided into observation group(59 cases)and control group(59 cases).The control group was treated with routine postoperative treatment,the observation group was treated with Tongxinluo capsule on the basis of the control group.The levels of inflammatory factors,restenosis indicators,the incidence of cardiovascular events and the incidence of adverse reactions were compared between the two groups of patients before and after 4 weeks of treatment.Results After 4 weeks of treatment,the levels of hs-CRP,IL-6,and TNF-αin the two groups were lower than before treatment(P<0.05),and the observation group was lower than the control group(P<0.01).After 6 months of follow-up,the incidence and degree of stenosis in the stent in the observation group were lower than those in the control group(P<0.05).The incidence of cardiovascular events in the observation group was 6.78%lower than that in the control group20.34%(χ~2=4.628,P=0.031).There was no significant difference in the incidence of adverse reactions between the two groups(χ~2=0.069,P=0.793).There were no serious adverse reactions in both groups,and the drug was not discontinued.Conclusion The application of Tongxinluo capsule in the patients with coronary heart disease is exact,which can help to relieve the inflammatory response,prevent the cardiovascular events,the restenosis in the stent and the high safety of the drug.
作者
张强
ZHANG Qiang(The People's Hospital of Dandong,Liaoning Province,Dandong 118000,China)
出处
《临床合理用药杂志》
2020年第11期1-3,共3页
Chinese Journal of Clinical Rational Drug Use
关键词
通心络胶囊
冠心病
冠脉介入术
炎性反应指标
再狭窄
心血管事件
Tongxinluo capsule
Coronary heart disease
Coronary intervention
Inflammatory response
Restenosis
Cardiovascular events
